[go: up one dir, main page]

WO2008131431A8 - Modulation of blood brain barrier protein expression - Google Patents

Modulation of blood brain barrier protein expression Download PDF

Info

Publication number
WO2008131431A8
WO2008131431A8 PCT/US2008/061316 US2008061316W WO2008131431A8 WO 2008131431 A8 WO2008131431 A8 WO 2008131431A8 US 2008061316 W US2008061316 W US 2008061316W WO 2008131431 A8 WO2008131431 A8 WO 2008131431A8
Authority
WO
WIPO (PCT)
Prior art keywords
brain barrier
blood brain
modulation
protein expression
barrier protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/061316
Other languages
French (fr)
Other versions
WO2008131431A2 (en
WO2008131431A3 (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
St Louis University
Original Assignee
St Louis University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by St Louis University filed Critical St Louis University
Priority to US12/597,458 priority Critical patent/US8466118B2/en
Publication of WO2008131431A2 publication Critical patent/WO2008131431A2/en
Publication of WO2008131431A3 publication Critical patent/WO2008131431A3/en
Publication of WO2008131431A8 publication Critical patent/WO2008131431A8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/03—Hydrolases acting on acid anhydrides (3.6) acting on acid anhydrides; catalysing transmembrane movement of substances (3.6.3)
    • C12Y306/03014—H+-transporting two-sector ATPase (3.6.3.14), i.e. F1 ATPase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)

Abstract

There are disclosed agents that inhibit Blood Brain Barrier Proteins (BBBP). Such agents are useful in controlling agents entering and exiting the CNS. This allows for drugs to be more effective and/or allowing side effects of the drugs to be lowered.
PCT/US2008/061316 2007-04-23 2008-04-23 Modulation of blood brain barrier protein expression Ceased WO2008131431A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/597,458 US8466118B2 (en) 2007-04-23 2008-04-23 Modulation of blood brain barrier protein expression

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92582007P 2007-04-23 2007-04-23
US60/925,820 2007-04-23

Publications (3)

Publication Number Publication Date
WO2008131431A2 WO2008131431A2 (en) 2008-10-30
WO2008131431A3 WO2008131431A3 (en) 2009-04-09
WO2008131431A8 true WO2008131431A8 (en) 2009-07-16

Family

ID=39876193

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/061316 Ceased WO2008131431A2 (en) 2007-04-23 2008-04-23 Modulation of blood brain barrier protein expression

Country Status (2)

Country Link
US (1) US8466118B2 (en)
WO (1) WO2008131431A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60138535D1 (en) * 2000-02-04 2009-06-10 Children S Hospital Res Founda USE OF LYSOSOMAL ACID LIPASE FOR THE TREATMENT OF ATHEROSCLEROSIS AND SIMILAR DISEASES
US20090297496A1 (en) * 2005-09-08 2009-12-03 Childrens Hospital Medical Center Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases
EP2209894B1 (en) * 2007-10-12 2015-06-03 The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin Method for opening tight junctions
JP2011514158A (en) * 2008-02-19 2011-05-06 エダン・バイオテクノロジー・インコーポレイテッド Antisense regulation of amyloid beta protein expression
RU2015151189A (en) 2010-04-23 2019-01-14 Синаджева Байофарма Корп ENZYME OF LYSOSOMAL ACID DISEASE
PL2977057T3 (en) 2010-09-09 2020-06-01 Alexion Pharmaceuticals, Inc. Isolated recombinant human n-glycosylated lysosomal acid lipase
KR20140006037A (en) 2011-02-15 2014-01-15 시나게바 바이오파르마, 코포레이션 Methods for treating lysosomal acid lipase deficiency
TWI721975B (en) 2015-04-16 2021-03-21 美商艾爾德生物製藥股份有限公司 Anti-pacap antibodies and uses thereof
JP7116685B2 (en) 2016-04-15 2022-08-10 エイチ． ルンドベック アー／エス Humanized anti-PACAP antibodies and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5220013A (en) * 1986-11-17 1993-06-15 Scios Nova Inc. DNA sequence useful for the detection of Alzheimer's disease
EP0332640A1 (en) 1986-11-17 1989-09-20 California Biotechnology, Inc. Recombinant alzheimer's amyloid protein
US5853985A (en) * 1988-08-30 1998-12-29 Bayer Aktiegsesellschaft Promoter of the gene for the human precursor of the alzheimer's disease and its use
DE971033T1 (en) * 1991-01-21 2001-05-03 Imperial College Of Science, Technology & Medicine Exam and model for Alzheimers disease
US7517644B1 (en) * 1991-08-23 2009-04-14 Larry J. Smith Method and compositions for cellular reprogramming
EP0644889A4 (en) * 1991-12-24 1996-01-10 Isis Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR MODULATING -g(b)-AMYLOID.
US5455169A (en) * 1992-06-04 1995-10-03 Alzheimer's Institute Of America, Inc. Nucleic acids for diagnosing and modeling Alzheimer's disease
US6310048B1 (en) 1999-12-09 2001-10-30 St. Louis University Antisense modulation of amyloid beta protein expression
US20050153914A1 (en) * 2001-05-18 2005-07-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of MDR P-glycoprotein gene expression using short interfering nucleic acid (siNA)
AU2002340267A1 (en) * 2001-10-19 2003-04-28 Memorial Sloan-Kettering Cancer Center Compositions and methods for reversal of drug resistance
US8168222B2 (en) * 2004-09-07 2012-05-01 Board Of Regents Of The University Of Nebraska Amphiphilic polymer-protein conjugates and methods of use thereof
US20090304676A1 (en) * 2005-11-10 2009-12-10 St. Louis University Compositions and methods for enhancing cognitive function
JP2011514158A (en) * 2008-02-19 2011-05-06 エダン・バイオテクノロジー・インコーポレイテッド Antisense regulation of amyloid beta protein expression

Also Published As

Publication number Publication date
US8466118B2 (en) 2013-06-18
WO2008131431A2 (en) 2008-10-30
US20100196393A1 (en) 2010-08-05
WO2008131431A3 (en) 2009-04-09

Similar Documents

Publication Publication Date Title
WO2008131431A8 (en) Modulation of blood brain barrier protein expression
WO2007044323A3 (en) Fusion proteins for blood-brain barrier delivery
IL184363A0 (en) Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
WO2010044879A3 (en) Method and devices for self adjusting phototherapeutic intervention
WO2008022349A3 (en) Agents for blood-brain barrier delivery
WO2007044534A3 (en) Vegf analogs and methods of use
WO2008076954A3 (en) Heterocycle compounds and methods of use thereof
PL2878297T3 (en) DRUGS FOR THE TREATMENT OR PREVENTION OF FIBERIAL DISEASES
WO2007146425A3 (en) Compounds and methods for treatment of chemotherapy-induced anemia
EP1761266A4 (en) COMPOUNDS, PREPARATIONS AND METHODS FOR TREATING OR PREVENTING SKIN INFLAMMATORY DISORDERS
WO2010034015A3 (en) Modulating the alternative complement pathway
WO2007095586A3 (en) Neuronal pain pathway modulators
WO2006127900A3 (en) Tl1a in the treatment of disease
WO2009150547A3 (en) 2-pyridyl substituted imidazoles as alk4 and/or alk4 inhibitors
IL209336B (en) Preparations for the treatment of overgrowth disorders and their uses
WO2009071689A3 (en) 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases
PL2818145T3 (en) Novel support system for treatment and prevention of diseases of the veins
WO2009045700A3 (en) 5-lipoxygenase-activating protein (flap) inhibitors
WO2007084535A3 (en) Neuronal nicotinic receptor ligands and their use
WO2007100430A3 (en) Cytisine and acetylcholine analogs and methods of treating mood disorders
DE602006007846D1 (en) Interaction between dietary protein and charged emulsifier
SI1912513T1 (en) Novel milk protein fractions and use thereof for preventing or treating chronic inflammatory diseases
WO2006094134A3 (en) Kim-1 antibodies for treatment of th2-mediated conditions
WO2009019433A3 (en) Fertilisation protein
FR2903906B1 (en) COMPOSITION FOR PREVENTING AND / OR TREATING DEGENERATIVE JOINT DISEASES.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08746695

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12597458

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 08746695

Country of ref document: EP

Kind code of ref document: A2